Do analysts recommend ABP or DRMA?

Dermata Therapeutics has a consensus price target of $10.00, indicating a potential upside of 687.40%. Given Dermata Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Dermata Therapeutics is more favorable than Abpro. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abpro 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Dermata Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation and earnings, ABP or DRMA?

Dermata Therapeutics is trading at a lower price-to-earnings ratio than Abpro, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abpro N/A N/A -$7.23M -$4.23 N/A Dermata Therapeutics N/A N/A -$7.56M -$5.31 N/A

Is ABP or DRMA more profitable?

Abpro's return on equity of 0.00% beat Dermata Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Abpro N/A N/A -344.76% Dermata Therapeutics N/A -127.91% -105.05%

Do analysts rate ABP or CDIO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abpro 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Cardio Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer ABP or APVO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abpro 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Aptevo Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33

Which has stronger earnings & valuation, ABP or APVO?

Abpro is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abpro N/A N/A -$7.23M -$4.23 N/A Aptevo Therapeutics N/A N/A -$25.97M -$197.60 N/A

Is ABP or APVO more profitable?

Abpro's return on equity of 0.00% beat Aptevo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Abpro N/A N/A -344.76% Aptevo Therapeutics N/A -198.50% -117.06%

Do analysts prefer INM or ABP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InMed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Abpro 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Do analysts prefer ABP or MBIO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abpro 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Mustang Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, ABP or MBIO?

Mustang Bio is trading at a lower price-to-earnings ratio than Abpro, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abpro N/A N/A -$7.23M -$4.23 N/A Mustang Bio N/A N/A -$1.92M -$0.48 N/A

Is ABP or MBIO more profitable?

Abpro's return on equity of 0.00% beat Mustang Bio's return on equity. Company Net Margins Return on Equity Return on Assets Abpro N/A N/A -344.76% Mustang Bio N/A -35.38% -16.36%

Abpro (ABP) Competitors

$0.52 0.00 (0.00%)

As of 07/17/2026

Compare

ABP vs. DRMA, CDIO, APVO, INM, and MBIO

Should you buy Abpro stock or one of its competitors? MarketBeat compares Abpro with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Abpro include Dermata Therapeutics (DRMA), Cardio Diagnostics (CDIO), Aptevo Therapeutics (APVO), InMed Pharmaceuticals (INM), and Mustang Bio (MBIO). These companies are all part of the "pharmaceutical products" industry.

How does Abpro compare to Dermata Therapeutics?

Abpro (NASDAQ:ABP) and Dermata Therapeutics (NASDAQ:DRMA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability.

23.3% of Abpro shares are held by institutional investors. Comparatively, 8.7% of Dermata Therapeutics shares are held by institutional investors. 13.7% of Abpro shares are held by insiders. Comparatively, 21.9% of Dermata Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Abpro's average media sentiment score of 0.00 equaled Dermata Therapeutics'average media sentiment score.

Company	Overall Sentiment
Abpro	Neutral
Dermata Therapeutics	Neutral

Dermata Therapeutics has a consensus price target of $10.00, indicating a potential upside of 687.40%. Given Dermata Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Dermata Therapeutics is more favorable than Abpro.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abpro	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Dermata Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Abpro's return on equity of 0.00% beat Dermata Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abpro	N/A	N/A	-344.76%
Dermata Therapeutics	N/A	-127.91%	-105.05%

Dermata Therapeutics is trading at a lower price-to-earnings ratio than Abpro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abpro	N/A	N/A	-$7.23M	-$4.23	N/A
Dermata Therapeutics	N/A	N/A	-$7.56M	-$5.31	N/A

Summary

Abpro and Dermata Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

How does Abpro compare to Cardio Diagnostics?

Abpro (NASDAQ:ABP) and Cardio Diagnostics (NASDAQ:CDIO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

Abpro has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -36,950.00%. Abpro's return on equity of 0.00% beat Cardio Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abpro	N/A	N/A	-344.76%
Cardio Diagnostics	-36,950.00%	-78.82%	-72.87%

Cardio Diagnostics has higher revenue and earnings than Abpro. Cardio Diagnostics is trading at a lower price-to-earnings ratio than Abpro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abpro	N/A	N/A	-$7.23M	-$4.23	N/A
Cardio Diagnostics	$10K	482.48	-$6.50M	-$3.38	N/A

23.3% of Abpro shares are held by institutional investors. Comparatively, 8.1% of Cardio Diagnostics shares are held by institutional investors. 13.7% of Abpro shares are held by company insiders. Comparatively, 13.3% of Cardio Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Cardio Diagnostics had 1 more articles in the media than Abpro. MarketBeat recorded 1 mentions for Cardio Diagnostics and 0 mentions for Abpro. Abpro's average media sentiment score of 0.00 equaled Cardio Diagnostics'average media sentiment score.

Company	Overall Sentiment
Abpro	Neutral
Cardio Diagnostics	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abpro	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Abpro beats Cardio Diagnostics on 6 of the 11 factors compared between the two stocks.

How does Abpro compare to Aptevo Therapeutics?

Abpro (NASDAQ:ABP) and Aptevo Therapeutics (NASDAQ:APVO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, earnings, risk and valuation.

Abpro is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abpro	N/A	N/A	-$7.23M	-$4.23	N/A
Aptevo Therapeutics	N/A	N/A	-$25.97M	-$197.60	N/A

In the previous week, Abpro's average media sentiment score of 0.00 equaled Aptevo Therapeutics'average media sentiment score.

Company	Overall Sentiment
Abpro	Neutral
Aptevo Therapeutics	Neutral

23.3% of Abpro shares are owned by institutional investors. Comparatively, 8.1% of Aptevo Therapeutics shares are owned by institutional investors. 13.7% of Abpro shares are owned by company insiders. Comparatively, 0.1% of Aptevo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Abpro's return on equity of 0.00% beat Aptevo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abpro	N/A	N/A	-344.76%
Aptevo Therapeutics	N/A	-198.50%	-117.06%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abpro	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Aptevo Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Summary

Abpro beats Aptevo Therapeutics on 5 of the 9 factors compared between the two stocks.

How does Abpro compare to InMed Pharmaceuticals?

InMed Pharmaceuticals (NASDAQ:INM) and Abpro (NASDAQ:ABP) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends.

Abpro has a net margin of 0.00% compared to InMed Pharmaceuticals' net margin of -132.87%. Abpro's return on equity of 0.00% beat InMed Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InMed Pharmaceuticals	-132.87%	-80.85%	-68.11%
Abpro	N/A	N/A	-344.76%

Abpro has lower revenue, but higher earnings than InMed Pharmaceuticals. InMed Pharmaceuticals is trading at a lower price-to-earnings ratio than Abpro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InMed Pharmaceuticals	$4.94M	1.02	-$8.16M	-$2.89	N/A
Abpro	N/A	N/A	-$7.23M	-$4.23	N/A

In the previous week, InMed Pharmaceuticals' average media sentiment score of 0.00 equaled Abpro'saverage media sentiment score.

Company	Overall Sentiment
InMed Pharmaceuticals	Neutral
Abpro	Neutral

20.1% of InMed Pharmaceuticals shares are held by institutional investors. Comparatively, 23.3% of Abpro shares are held by institutional investors. 0.9% of InMed Pharmaceuticals shares are held by company insiders. Comparatively, 13.7% of Abpro shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InMed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Abpro	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

Abpro beats InMed Pharmaceuticals on 7 of the 10 factors compared between the two stocks.

How does Abpro compare to Mustang Bio?

Abpro (NASDAQ:ABP) and Mustang Bio (NASDAQ:MBIO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.

Abpro's return on equity of 0.00% beat Mustang Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abpro	N/A	N/A	-344.76%
Mustang Bio	N/A	-35.38%	-16.36%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abpro	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Mustang Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

23.3% of Abpro shares are held by institutional investors. Comparatively, 10.0% of Mustang Bio shares are held by institutional investors. 13.7% of Abpro shares are held by company insiders. Comparatively, 4.0% of Mustang Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Abpro's average media sentiment score of 0.00 equaled Mustang Bio'saverage media sentiment score.

Company	Overall Sentiment
Abpro	Neutral
Mustang Bio	Neutral

Mustang Bio is trading at a lower price-to-earnings ratio than Abpro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abpro	N/A	N/A	-$7.23M	-$4.23	N/A
Mustang Bio	N/A	N/A	-$1.92M	-$0.48	N/A

Summary

Abpro beats Mustang Bio on 5 of the 8 factors compared between the two stocks.

Get Abpro News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABP vs. The Competition

Export

Metric	Abpro	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.42M	$3.69B	$6.89B	$12.28B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-0.12	20.49	27.07	23.94
Price / Sales	N/A	300.32	515.45	90.30
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	-0.06	7.92	10.42	6.14
Net Income	-$7.23M	$23.81M	$3.60B	$331.74M
7 Day Performance	N/A	-1.09%	-1.26%	-1.81%
1 Month Performance	N/A	2.56%	1.07%	-1.44%
1 Year Performance	-92.34%	42.16%	23.61%	16.33%

Abpro Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABP Abpro	N/A	$0.52 flat	N/A	N/A	$1.42M	N/A	N/A	15
DRMA Dermata Therapeutics	2.0776 of 5 stars	$1.40 -0.7%	$10.00 +614.3%	-81.2%	$5.67M	N/A	N/A	8	Gap Down
CDIO Cardio Diagnostics	0.2444 of 5 stars	$1.92 +0.5%	N/A	-62.1%	$5.65M	$10K	N/A	1	Gap Up
APVO Aptevo Therapeutics	0.7357 of 5 stars	$4.50 -0.2%	N/A	-91.3%	$5.62M	N/A	N/A	50	High Trading Volume
INM InMed Pharmaceuticals	0.9395 of 5 stars	$1.65 -1.2%	N/A	-43.1%	$5.53M	$4.94M	N/A	10	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABP) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Abpro (ABP) Competitors

ABP vs. DRMA, CDIO, APVO, INM, and MBIO

How does Abpro compare to Dermata Therapeutics?

Summary

How does Abpro compare to Cardio Diagnostics?

Summary

How does Abpro compare to Aptevo Therapeutics?

Summary

How does Abpro compare to InMed Pharmaceuticals?

Summary

How does Abpro compare to Mustang Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABP vs. The Competition

Abpro Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Abpro (ABP) Competitors

ABP vs. DRMA, CDIO, APVO, INM, and MBIO

How does Abpro compare to Dermata Therapeutics?

Do institutionals and insiders have more ownership in ABP or DRMA?

Does the media refer more to ABP or DRMA?

Do analysts recommend ABP or DRMA?

Is ABP or DRMA more profitable?

Which has stronger valuation and earnings, ABP or DRMA?

Summary

How does Abpro compare to Cardio Diagnostics?

Is ABP or CDIO more profitable?

Which has higher valuation & earnings, ABP or CDIO?

Do institutionals and insiders hold more shares of ABP or CDIO?

Does the media refer more to ABP or CDIO?

Do analysts rate ABP or CDIO?

Summary

How does Abpro compare to Aptevo Therapeutics?

Which has stronger earnings & valuation, ABP or APVO?

Does the media refer more to ABP or APVO?

Do institutionals and insiders believe in ABP or APVO?

Is ABP or APVO more profitable?

Do analysts prefer ABP or APVO?

Summary

How does Abpro compare to InMed Pharmaceuticals?

Is INM or ABP more profitable?

Which has preferable earnings and valuation, INM or ABP?

Does the media refer more to INM or ABP?

Do insiders and institutionals have more ownership in INM or ABP?

Do analysts prefer INM or ABP?

Summary

How does Abpro compare to Mustang Bio?

Is ABP or MBIO more profitable?

Do analysts prefer ABP or MBIO?

Do insiders & institutionals have more ownership in ABP or MBIO?

Does the media refer more to ABP or MBIO?

Which has stronger valuation and earnings, ABP or MBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABP vs. The Competition

Abpro Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools